The authoritative resource to stay up to date with facts, explanation and interpretation.
Plus: New faces at organizations seeking to improve clinical trials
The CCO role is evolving, argue John Archer and Roger Longman, as applicants must challenge entrenched views and manage a growing set of stakeholders with creativity
Also in BioCentury’s Clinical Report: CG’s oncolytic virus success, ivonescimab’s latest lung cancer win, and more
It isn’t clear whether staffing cuts or loss of FDA champions have caused FDA to miss the PDUFA goal for an ultrarare disease therapy
On BioCentury’s latest podcast: Why tau may be approaching a tipping point for Alzheimer’s drug development
With headlines dominated by Merck KGaA/Springworks deal, smaller companies make deals to advance programs
FDA, HHS allow political appointees to make regulatory decisions about Novavax’s COVID vaccine based on unscientific rationales
GSK’s Jemperli leads to sustained clinical complete responses in 95% of rectal cancer patients
Political interference in product reviews threatens to undermine FDA’s credibility
German pharma adds drugs for rare tumors, expands U.S. footprint via $3.9B acquisition
How the landscape is shaping up in MG
An IPO opening for Asian biotechs
Seven new products get positive opinions in April
Plus: Flagship unveils disease interception play Etiome; Verastem raises $75M PIPE; and more
A preview of BioCentury’s U.S. Grand Rounds meeting in Chicago
